Skip to content
Peptigraph home

Survodutide

GLP-1 / glucagon dual agonist. Survodutide is investigational and not approved for any use.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusInvestigational · phase 3Prohibited by WADA (S0)Full legal history

Key facts

Class
GLP-1 / glucagon dual agonist
Also called
No common aliases
Half-life
Not found
No published half-life found (PubMed search, 2 Oct 2026)
FDA status
Not approved
Investigational · phase 3
WADA
Prohibited (S0)
In and out of competition
Everything on Survodutide

Survodutide guides

Researched for

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

Survodutide: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
DiabetesNot in our ledgerNot in our ledger3Human RCT evidence, 4 of 4The New England journal of medicine 2026, PMID 42820639
Heart healthNot in our ledgerNot in our ledger1No graded study for this goal
LiverNot in our ledgerNot in our ledger3Human RCT evidence, 4 of 4Nature medicine 2026, PMID 42252333
Weight lossNot in our ledgerNot in our ledger8Human RCT evidence, 4 of 4The New England journal of medicine 2026, PMID 42253238

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

A glucagon and GLP-1 dual agonist with a liver trial

Survodutide is a glucagon and GLP-1 receptor dual agonist.[11]

In a phase 2 trial in MASH, improvement with no worsening of fibrosis occurred in 47% at 2.4 mg, 62% at 4.8 mg and 43% at 6.0 mg, against 14% on placebo.[12]

Strongest finding and cost

In the phase 3 obesity trial SYNCHRONIZE-1, mean body-weight change at week 76 was -12.2% at 3.6 mg and -13.0% at 6.0 mg, against -5.4% on placebo.[4]

In adults with obesity and type 2 diabetes, weight change at week 76 was smaller: -8.2% at 3.6 mg and -9.8% at 6.0 mg, against -3.9% on placebo.[9]

In the phase 2 obesity trial, adverse events occurred in 91% of survodutide recipients and 75% of placebo recipients, mostly gastrointestinal.[11]

Regulatory path

Drugs@FDA lists no survodutide product.[2]

WADA does not list survodutide by name. As an unapproved drug in development it falls under the S0 clause.[1]

Common questions

Is Survodutide FDA approved?

No. Survodutide is investigational (investigational · phase 3) and not approved for any use.

Is Survodutide banned in sport?

Yes. Prohibited by WADA (S0), so it is prohibited at all times for tested athletes.

What is survodutide?

An investigational glucagon and GLP-1 receptor dual agonist.[11]

What are the survodutide clinical trials?

In the phase 3 obesity trial SYNCHRONIZE-1, week-76 weight change was -12.2% at 3.6 mg and -13.0% at 6.0 mg, against -5.4% on placebo.[4]

Does survodutide help the liver?

In a phase 3 trial in adults with obesity and at-risk MASLD, 84.2% of those on survodutide 6.0 mg versus 24.3% on placebo had at least a 30% reduction in liver fat by week 48.[10]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "survodutide" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  4. 4Survodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · 2026PMID 42253238Accessed 2 Oct 2026
  5. 5PubMed search: survodutide[tiab] OR BI456906[tiab] (86 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: (survodutide[tiab] OR BI456906[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (56 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: (survodutide[tiab] OR BI456906[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: (SYNCHRONIZE[tiab] OR TRIUMPH[tiab] OR GLORY[tiab] OR DREAMS[tiab]) AND (survodutide[tiab] OR retatrutide[tiab] OR mazdutide[tiab]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026PMID 42820639Accessed 2 Oct 2026
  10. 10Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · 2026PMID 42252333Accessed 2 Oct 2026
  11. 11Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.The lancet. Diabetes & endocrinology · 2024PMID 38330987Accessed 2 Oct 2026
  12. 12A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.The New England journal of medicine · 2024PMID 38847460Accessed 2 Oct 2026

Found an error? Report a correction.